The Efficacy and Safety of Y-3 Intracalvariosseous Injection Versus Intravenous Injection in the Treatment of Acute Large Hemispheric Infarction

NARecruitingINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

April 22, 2024

Primary Completion Date

March 15, 2026

Study Completion Date

March 15, 2027

Conditions
Stroke, Acute IschemicBlood-Brain Barrier
Interventions
PROCEDURE

Y-3 ICO injection

Patients included will be given skull outer plate drilling surgery and Y-3 ICO injection under local anesthesia and sedation. The injection will be given for 3 consecutive days.

DRUG

Y-3 intravenous injection

Patients included will be given Y-3 intravenous injection for 7 consecutive days.

OTHER

Conventional treatment

standard treatment and management according to related guidelines during the entire treatment period

Trial Locations (6)

100050

RECRUITING

Beijing Tiantan Hospital, Beijing

Unknown

RECRUITING

The first affiliated hospital of Wannan Medical College, Wuhu

RECRUITING

North China University of Science and Technology Affiliated Hospital, Tangshan

WITHDRAWN

Tangshan Municipal Worker's Hospital, Tangshan

RECRUITING

Shaanxi Provincial People's Hospital, Xi'an

RECRUITING

Tianjin Huanhu hospital, Tianjin

All Listed Sponsors
lead

yilong Wang

OTHER

NCT06374667 - The Efficacy and Safety of Y-3 Intracalvariosseous Injection Versus Intravenous Injection in the Treatment of Acute Large Hemispheric Infarction | Biotech Hunter | Biotech Hunter